Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2023-02-07 00:00:00 ET · period of report 2023-02-03 · accession 0001415889-23-002070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-07 | 2023-02-03 | HALO | Duncan Barbara Gayle | Dir | A - Grant | $0.00 | +1,188 | 1,188 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-03 | A | A | 1,188 | $0.00 | 1,188 | D | — | — | (F1) Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. |